{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:37:21Z","timestamp":1784864241209,"version":"3.55.0"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.blre.2022.100999","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T21:32:59Z","timestamp":1660339979000},"page":"100999","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The use of bone-modifying agents in multiple myeloma"],"prefix":"10.1016","volume":"57","author":[{"given":"Munawwar","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.blre.2022.100999_bb0005","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0015","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.blre.2022.100999_bb0020","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1111\/bph.14889","article-title":"Therapeutic targets in myeloma bone disease","volume":"178","author":"Marino","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.blre.2022.100999_bb0025","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.blre.2022.100999_bb0030","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100999_bb0035","first-page":"2171","article-title":"Multiple myeloma patients and risk of skeletal related events - real-world evidence in US oncology clinics","volume":"130","author":"Bhatta","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2022.100999_bb0040","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bone.2008.01.027","article-title":"The pathogenesis of the bone disease of multiple myeloma","volume":"42","author":"Edwards","year":"2008","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.blre.2022.100999_bb0045","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2022.100999_bb0050","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100999_bb0055","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jdsr.2021.08.006","article-title":"Pathogenesis and treatment of multiple myeloma bone disease","volume":"57","author":"Hiasa","year":"2021","journal-title":"Jpn Dental Sci Rev"},{"issue":"8","key":"10.1016\/j.blre.2022.100999_bb0060","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrg1122","article-title":"Genetic regulation of osteoclast development and function","volume":"4","author":"Teitelbaum","year":"2003","journal-title":"Nat Rev Genet"},{"issue":"2","key":"10.1016\/j.blre.2022.100999_bb0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.blre.2022.100999_bb0070","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.2741\/2296","article-title":"Signaling and transcriptional regulation in osteoblast commitment and differentiation","volume":"12","author":"Huang","year":"2007","journal-title":"Front Biosci"},{"key":"10.1016\/j.blre.2022.100999_bb0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4137\/CGM.S16817","article-title":"Bone disease in multiple myeloma: pathophysiology and management","volume":"7","author":"Hameed","year":"2014","journal-title":"Cancer Growth Metastasis"},{"issue":"8","key":"10.1016\/j.blre.2022.100999_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10518","article-title":"The role of bone-modifying agents in myeloma bone disease","volume":"5","author":"Lu","year":"2021","journal-title":"JBMR Plus"},{"issue":"2","key":"10.1016\/j.blre.2022.100999_bb0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","article-title":"Myeloma bone disease: pathophysiology and management","volume":"2","author":"Silbermann","year":"2013","journal-title":"J Bone Oncol"},{"issue":"16","key":"10.1016\/j.blre.2022.100999_bb0090","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2009-03-211920","article-title":"Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease","volume":"114","author":"Kukreja","year":"2009","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.blre.2022.100999_bb0095","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2022.100999_bb0100","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.blre.2022.100999_bb0105","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.exphem.2004.03.015","article-title":"New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL)","volume":"32","author":"Giuliani","year":"2004","journal-title":"Exp Hematol"},{"issue":"6","key":"10.1016\/j.blre.2022.100999_bb0110","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2022.100999_bb0115","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/bbrc.1998.9788","article-title":"RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis","volume":"253","author":"Nakagawa","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.blre.2022.100999_bb0120","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/blood-2008-01-132134","article-title":"Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.blre.2022.100999_bb0130","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","article-title":"The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.blre.2022.100999_bb0135","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3816\/CLM.2009.n.085","article-title":"Serum levels of total-RANKL in multiple myeloma","volume":"9","author":"Jakob","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"13","key":"10.1016\/j.blre.2022.100999_bb0140","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2022.100999_bb0145","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2022.100999_bb0150","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0155","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.blre.2022.100999_bb0160","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.blre.2022.100999_bb0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000094676","article-title":"Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: case reports","volume":"116","author":"Henrich","year":"2006","journal-title":"Acta Haematol"},{"issue":"2","key":"10.1016\/j.blre.2022.100999_bb0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/j.blre.2022.100999_bb0175","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.1016\/j.blre.2022.100999_bb0180","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1359\/jbmr.080617","article-title":"Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo","volume":"23","author":"Plotkin","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.blre.2022.100999_bb0185","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00228-012-1216-7","article-title":"Bisphosphonates: effects on osteoblast","volume":"68","author":"Maruotti","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.blre.2022.100999_bb0190","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0195","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: mechanisms of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.blre.2022.100999_bb0200","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"8827","key":"10.1016\/j.blre.2022.100999_bb0205","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet (London, England)"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.100999_bb0210","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/8756-3282(91)90064-P","article-title":"The use of clodronate in multiple myeloma","volume":"12","author":"Delmas","year":"1991","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.blre.2022.100999_bb0215","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00223-014-9903-2","article-title":"Effect of clodronate treatment on risk of fracture: a systematic review and meta-analysis","volume":"95","author":"Frediani","year":"2014","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"10.1016\/j.blre.2022.100999_bb0220","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia study group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2022.100999_bb0225","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.blre.2022.100999_bb0230","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J (Sudbury, Mass)"},{"issue":"24","key":"10.1016\/j.blre.2022.100999_bb0235","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1158\/1078-0432.CCR-13-2275","article-title":"Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis","volume":"19","author":"Palmieri","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.blre.2022.100999_bb0245","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2022.100999_bb0250","first-page":"331","article-title":"Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients","volume":"7","author":"Yee","year":"2012","journal-title":"Clin Interv Aging"},{"issue":"6937","key":"10.1016\/j.blre.2022.100999_bb0255","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.blre.2022.100999_bb0260","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.blre.2022.100999_bb0265","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0270","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1185\/03007995.2015.1105795","article-title":"A comprehensive review of denosumab for bone metastasis in patients with solid tumors","volume":"32","author":"G\u00fcl","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"35","key":"10.1016\/j.blre.2022.100999_bb0275","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9768","key":"10.1016\/j.blre.2022.100999_bb0280","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.blre.2022.100999_bb0285","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.blre.2022.100999_bb0290","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(18)30075-5","article-title":"Denosumab for myeloma bone disease: ready for prime time?","volume":"19","author":"Dimopoulos","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2022.100999_bb0295","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.blre.2022.100999_bb0300","doi-asserted-by":"crossref","first-page":"E2113","DOI":"10.3390\/cancers12082113","article-title":"Multiple myeloma associated bone disease","volume":"12","author":"Rasch","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2022.100999_bb0305","article-title":"Efficacy and safety of denosumab in multiple myeloma","author":"Kitagawa","year":"2016","journal-title":"[Rinsho ketsueki] Jpn J Clin Hematol"},{"issue":"6","key":"10.1016\/j.blre.2022.100999_bb0310","first-page":"1657","article-title":"Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency","volume":"23","author":"Watkins","year":"2015","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.blre.2022.100999_bb0315","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0320","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping denosumab","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"10.1016\/j.blre.2022.100999_bb0325","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.blre.2022.100999_bb0330","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3324\/haematol.2017.185264","article-title":"Denosumab for bone lesions in multiple myeloma - what is its value?","volume":"103","author":"Goldstein","year":"2018","journal-title":"Haematologica."},{"issue":"2","key":"10.1016\/j.blre.2022.100999_bb0335","doi-asserted-by":"crossref","first-page":"E265","DOI":"10.3390\/cancers12020265","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"12","author":"Ito","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.blre.2022.100999_bb0340","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2007-03-067710","article-title":"Myeloma bone disease and proteasome inhibition therapies","volume":"110","author":"Terpos","year":"2007","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.100999_bb0345","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3324\/haematol.2010.031302","article-title":"A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients","volume":"96","author":"Zangari","year":"2011","journal-title":"Haematologica."},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0350","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.4081\/hr.2018.7401","article-title":"Bone-targeted agents in multiple myeloma","volume":"10","author":"Nishida","year":"2018","journal-title":"Hematol Rep"},{"issue":"9","key":"10.1016\/j.blre.2022.100999_bb0355","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia."},{"issue":"11","key":"10.1016\/j.blre.2022.100999_bb0360","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/107999003322558782","article-title":"Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6","volume":"23","author":"Dicuonzo","year":"2003","journal-title":"J Interferon Cytokine Res"},{"issue":"2","key":"10.1016\/j.blre.2022.100999_bb0365","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.blre.2022.100999_bb0370","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2022.100999_bb0375","doi-asserted-by":"crossref","DOI":"10.1359\/jbmr.081016","article-title":"Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion","author":"Srivastava","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2022.100999_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.blre.2022.100999_bb0385","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.blre.2022.100999_bb0390","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00198-011-1563-8","article-title":"Treatment with acetaminophen\/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg","volume":"23","author":"Wark","year":"2012","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.blre.2022.100999_bb0395","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00198-010-1448-2","article-title":"Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid","volume":"22","author":"Silverman","year":"2011","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.blre.2022.100999_bb0400","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.blre.2022.100999_bb0405","article-title":"Role of Bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update summary","author":"Poznak","year":"2017","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.blre.2022.100999_bb0410","author":"Anderson"},{"issue":"9","key":"10.1016\/j.blre.2022.100999_bb0415","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.blre.2022.100999_bb0420","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/471035","article-title":"Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment","volume":"2014","author":"Rasmusson","year":"2014","journal-title":"Int J Dent"},{"issue":"7","key":"10.1016\/j.blre.2022.100999_bb0425","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","article-title":"Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy","volume":"65","author":"Wang","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"6","key":"10.1016\/j.blre.2022.100999_bb0430","first-page":"1905","article-title":"A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer","volume":"26","author":"Schiodt","year":"2018","journal-title":"Support Care Cancer"},{"issue":"34","key":"10.1016\/j.blre.2022.100999_bb0435","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2022.100999_bb0440","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.joms.2006.03.002","article-title":"Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors","volume":"64","author":"Delibasi","year":"2006","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.blre.2022.100999_bb0445","doi-asserted-by":"crossref","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2022.100999_bb0450","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","author":"Zervas","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2022.100999_bb0455","doi-asserted-by":"crossref","DOI":"10.1200\/JOP.19.00384","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline summary","author":"Shapiro","year":"2019","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.blre.2022.100999_bb0460","series-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","author":"Saad","year":"2012"},{"issue":"26","key":"10.1016\/j.blre.2022.100999_bb0465","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial","volume":"38","author":"Sim","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0470","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2022.100999_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.joms.2008.11.015","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients","author":"Lazarovici","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.blre.2022.100999_bb0480","doi-asserted-by":"crossref","DOI":"10.1002\/hed.21019","article-title":"Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach","author":"Tirelli","year":"2009","journal-title":"Head Neck"},{"issue":"8","key":"10.1016\/j.blre.2022.100999_bb0485","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European myeloma network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.blre.2022.100999_bb0490","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3899\/jrheum.080759","article-title":"Bisphosphonate associated osteonecrosis of the jaw","volume":"36","author":"Khan","year":"2009","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.blre.2022.100999_bb0495","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","author":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.blre.2022.100999_bb0500","author":"PRIME PubMed"},{"key":"10.1016\/j.blre.2022.100999_bb0505","doi-asserted-by":"crossref","DOI":"10.1200\/JOP.19.00645","article-title":"Comment on medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline summary","author":"Fusco","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"10.1016\/j.blre.2022.100999_bb0510","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00130404-200207000-00012","article-title":"Electrolyte abnormalities with zoledronic acid therapy","volume":"8","author":"Sorscher","year":"2002","journal-title":"Cancer J"},{"key":"10.1016\/j.blre.2022.100999_bb0515","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2014.13979","article-title":"Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature","volume":"144","author":"Kreutle","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.blre.2022.100999_bb0520","article-title":"Acute severe diarrhoea and hyponatremia after zoledronic acid infusion: an acute phase reaction","author":"Kuchay","year":"2017","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.blre.2022.100999_bb0525","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM200304103481521","article-title":"Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency","author":"Rosen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.100999_bb0530","doi-asserted-by":"crossref","DOI":"10.1359\/jbmr.2001.16.9.1719","article-title":"Bisphosphonate therapy for Paget\u2019s disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission","author":"Stuckey","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.blre.2022.100999_bb0535","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/2040622315584114","article-title":"Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications","volume":"6","author":"Saita","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"issue":"11","key":"10.1016\/j.blre.2022.100999_bb0540","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/pds.4045","article-title":"Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting","volume":"25","author":"Huynh","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.blre.2022.100999_bb0545","article-title":"The calcium culprit: a case of Denosumab-induced hypocalcemia","volume":"11","author":"Kalayanamitra","year":"2019","journal-title":"Cureus."},{"key":"10.1016\/j.blre.2022.100999_bb0550","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1704460114","article-title":"Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance","author":"Lloyd","year":"2017","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"10.1016\/j.blre.2022.100999_bb0555","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.blre.2022.100999_bb0560","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.injury.2018.09.014","article-title":"Frequency and associated factor of atypical periprosthetic femoral fracture after hip arthroplasty","volume":"49","author":"Lee","year":"2018","journal-title":"Injury."},{"issue":"10","key":"10.1016\/j.blre.2022.100999_bb0565","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines","volume":"17","author":"Kumar","year":"2019","journal-title":"JNCCN J Nat Compr Cancer Network"},{"issue":"4","key":"10.1016\/j.blre.2022.100999_bb0570","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2022.100999_bb0575","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.560","article-title":"Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures","author":"Donnelly","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.blre.2022.100999_bb0580","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2169\/internalmedicine.37.396","article-title":"Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate","volume":"37","author":"C\u00f6mlek\u00e7i","year":"1998","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0585","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1186\/s13018-020-01941-x","article-title":"Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy","volume":"15","author":"D\u00f3zsai","year":"2020","journal-title":"J Orthop Surg Res"},{"issue":"9","key":"10.1016\/j.blre.2022.100999_bb0590","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00198-008-0585-3","article-title":"Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs","volume":"19","author":"Saito","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.blre.2022.100999_bb0595","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100999_bb0600","article-title":"(18)F-FDG PET\/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders","author":"Dammacco","year":"2014","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.blre.2022.100999_bb0605","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2011.08573.x","article-title":"Guidelines for the diagnosis and management of multiple myeloma 2011","author":"Bird","year":"2011","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2022.100999_bb0610","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/bjh.17256","article-title":"Controversies in the use of new bone-modifying therapies in multiple myeloma","volume":"193","author":"Terpos","year":"2021","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2022.100999_bb0615","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European myeloma network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematol Suppl"},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0620","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"JNCCN J Nat Compr Cancer Network"},{"key":"10.1016\/j.blre.2022.100999_bb0625","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100999_bb0630","doi-asserted-by":"crossref","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0635","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with Bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA."},{"issue":"6","key":"10.1016\/j.blre.2022.100999_bb0640","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1078-0432.CCR-15-1864","article-title":"Bone Marker\u2013directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: results of the Z-MARK study","volume":"22","author":"Raje","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2022.100999_bb0645","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.blre.2022.100999_bb0650","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2 Suppl 6","key":"10.1016\/j.blre.2022.100999_bb0655","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0093-7754(01)90261-1","article-title":"Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program","volume":"28","author":"Major","year":"2001","journal-title":"Semin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2022.100999_bb0660","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1023\/A:1008238422151","article-title":"Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease","volume":"8","author":"Vinholes","year":"1997","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.blre.2022.100999_bb0665","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.blre.2022.100999_bb0670","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2022.100999_bb0675","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2022.100999_bb0680","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC working party on leukaemia in adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"issue":"8827","key":"10.1016\/j.blre.2022.100999_bb0685","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlledmulticentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2022.100999_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic myeloma study group): a double-blind, randomised controlled trial","author":"Gimsing","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2022.100999_bb0695","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2014.924117","article-title":"Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma","author":"Sanfilippo","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2022.100999_bb0700","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","article-title":"Role and mechanism of action of sclerostin in bone","volume":"96","author":"Delgado-Calle","year":"2017","journal-title":"Bone."},{"key":"10.1016\/j.blre.2022.100999_bb0705","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0710","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.blre.2022.100999_bb0715","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2022.100999_bb0720","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/8755122520967632","article-title":"Romosozumab: a novel agent in the treatment for postmenopausal osteoporosis","volume":"37","author":"Miller","year":"2021","journal-title":"J Pharm Technol"},{"issue":"26","key":"10.1016\/j.blre.2022.100999_bb0725","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100999_bb0730","article-title":"Dickkopf-1 negatively regulates the expression of osteoprotegerin, a key osteoclastogenesis inhibitor, by sequestering Lrp6 in primary and metastatic lytic bone lesions","author":"Wang","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.blre.2022.100999_bb0735","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100999_bb0740","author":"Novartis Pharmaceuticals"},{"key":"10.1016\/j.blre.2022.100999_bb0745","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820945770","article-title":"Long noncoding RNA LUCAT1 promotes multiple myeloma cell growth by regulating the TGF-\u03b2 signaling pathway","volume":"19","author":"Liu","year":"2020","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.blre.2022.100999_bb0750","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bone.2016.07.007","article-title":"Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease","volume":"91","author":"Nyman","year":"2016","journal-title":"Bone."},{"key":"10.1016\/j.blre.2022.100999_bb0755","series-title":"Encyclopedia of endocrine diseases","article-title":"Multiple myeloma bone disease","author":"Terpos","year":"2019"},{"issue":"6","key":"10.1016\/j.blre.2022.100999_bb0760","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2022.100999_bb0765","author":"Silbermann"},{"key":"10.1016\/j.blre.2022.100999_bb0770","author":"MD AY"},{"key":"10.1016\/j.blre.2022.100999_bb0775","author":"Novartis Pharmaceuticals"},{"key":"10.1016\/j.blre.2022.100999_bb0785","author":"MD AY"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2200073X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2200073X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:31:33Z","timestamp":1759437093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X2200073X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":155,"alternative-id":["S0268960X2200073X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.100999","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of bone-modifying agents in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.100999","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100999"}}